ArticleDiscover oncology2026

Development and validation of a cuproptosis-immune prognostic signature for risk stratification and personalized therapy in cutaneous melanoma.

Meiru Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.